Armata Pharmaceuticals will present positive topline data from the SWARM-P.a. clinical study at the North American Cystic Fibrosis Conference November 3rd in Phoenix, AZ, highlighting results of their novel inhaled multi-phage therapeutic for treating chronic pulmonary P. aeruginosa infections in people with CF.